Stoked Bio is developing a portfolio of novel therapeutics to treat infectious diseases and cancers resistant to current therapeutic options.

In both of these areas there is a massive need for new treatment options.

Antimicrobial Resistance (AMR) is a huge issue for the health care industry as more and more infections can no longer be treated, putting lives at risk.

But how can we focus on two different areas? We don’t…AMR is a significant issue facing Cancer patients. 

Developing new Antibiotics and Antifungals is developing new treatments for Cancer patients.

Infection is the primary cause of hospitalization for one in five cancer patients undergoing treatment.

The weakened immune system of cancer patients undergoing chemotherapy greatly increases their vulnerability to drug-resistant bacterial infections such as: 

• Escherichia coli, 
• Staphylococcus aureus, 
• Acinetobacter baumannii, 
• Pseudomonas aeruginosa

According to the current estimation, the mortality rate due to severe sepsis is 8.5% in cancer patients. Major causes of sepsis are E. coli and S. aureus infections.

Hematological cancer patients demonstrated a 62% mortality rate and a 5.6x increase in odds of mortality following a Carbapenem-resistant gram-negative infection.